BR112017002629A2 - decoys de oligonucleotídeo para o tratamento de dor - Google Patents
decoys de oligonucleotídeo para o tratamento de dorInfo
- Publication number
- BR112017002629A2 BR112017002629A2 BR112017002629-5A BR112017002629A BR112017002629A2 BR 112017002629 A2 BR112017002629 A2 BR 112017002629A2 BR 112017002629 A BR112017002629 A BR 112017002629A BR 112017002629 A2 BR112017002629 A2 BR 112017002629A2
- Authority
- BR
- Brazil
- Prior art keywords
- oligonucleotide decoys
- pain treatment
- decoys
- double
- nucleic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
são providos agentes terapêuticos tais como os ácidos nucleicos de fita dupla, denominados decoys de oligonucleotídeo, com-posições farmacêuticas compreendendo os mesmos, e métodos relacionados para a modulação de sinalização nociceptiva, por exemplo, para prevenir e/ou tratar a dor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462037996P | 2014-08-15 | 2014-08-15 | |
US62/037,996 | 2014-08-15 | ||
PCT/US2015/045268 WO2016025829A1 (en) | 2014-08-15 | 2015-08-14 | Oligonucleotide decoys for the treatment of pain |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017002629A2 true BR112017002629A2 (pt) | 2018-02-20 |
Family
ID=55304669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017002629-5A BR112017002629A2 (pt) | 2014-08-15 | 2015-08-14 | decoys de oligonucleotídeo para o tratamento de dor |
Country Status (11)
Country | Link |
---|---|
US (2) | US10287583B2 (pt) |
EP (2) | EP3180434B1 (pt) |
JP (2) | JP6705807B2 (pt) |
CN (1) | CN106661578B (pt) |
AU (1) | AU2015301491A1 (pt) |
BR (1) | BR112017002629A2 (pt) |
CA (1) | CA2957250A1 (pt) |
ES (1) | ES2750689T3 (pt) |
PT (1) | PT3180434T (pt) |
RU (1) | RU2017108238A (pt) |
WO (1) | WO2016025829A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5646320B2 (ja) | 2007-05-11 | 2014-12-24 | アダイニクス, インコーポレイテッド | 遺伝子発現と疼痛 |
CA2872901A1 (en) | 2012-05-10 | 2013-11-14 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
JP6705807B2 (ja) | 2014-08-15 | 2020-06-03 | エーダイニクス インコーポレイテッド | 疼痛を治療するためのオリゴヌクレオチドデコイ |
FR3029450B1 (fr) * | 2014-12-03 | 2017-11-03 | Pole De Plasturgie De Lest | Dispositif de moulage pour la fabrication de pieces en materiau composite a partir de resine polymere liquide par injection haute pression. |
EP3902550A4 (en) * | 2018-12-24 | 2023-09-06 | The Regents of the University of California | TREATMENT OF SPINE DISEASES WITH CHIMERA DECOY |
EP4196587A2 (en) * | 2020-08-13 | 2023-06-21 | Nevada Research & Innovation Corporation | Klf11 sirna for treatment of diabetes and obesity |
WO2023070072A1 (en) | 2021-10-21 | 2023-04-27 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Retroelement-generated transcription factor decoys |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
KR100225087B1 (ko) | 1990-03-23 | 1999-10-15 | 한스 발터라벤 | 피타아제의 식물내 발현 |
US5272056A (en) | 1991-01-03 | 1993-12-21 | The Research Foundation Of State University Of New York | Modification of DNA and oligonucleotides using metal complexes of polyaza ligands |
US5683985A (en) | 1991-04-18 | 1997-11-04 | The Salk Institute For Biological Studies | Oligonucleotide decoys and methods relating thereto |
FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
JPH07501204A (ja) | 1991-06-28 | 1995-02-09 | マサチューセッツ インスティテュート オブ テクノロジー | 局所的オリゴヌクレオチド療法 |
WO1995004064A1 (en) | 1993-07-29 | 1995-02-09 | The Regents Of The University Of California | Polynucleotide decoys that ihnibit mhc-ii expression and uses thereof |
EP1340505A3 (en) | 1993-10-29 | 2004-07-14 | The Brigham And Women's Hospital, Inc. | Therapeutic use of cis-element decoys in vivo |
JP3392143B2 (ja) | 1994-11-17 | 2003-03-31 | 大鵬薬品工業株式会社 | 二本鎖オリゴヌクレオチド及びこれを有効成分とする制癌剤 |
AU5369396A (en) | 1995-03-23 | 1996-10-08 | Research Foundation Of The State University Of New York, The | Rest protein and dna |
KR100449677B1 (ko) | 1995-05-11 | 2004-11-20 | 어플라이드 리서치 시스템스 | Il-6 활성 저해 물질 |
DE69636997T2 (de) | 1995-05-12 | 2007-07-12 | Anges MG Inc., Ibaraki | HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN |
GB9515356D0 (en) | 1995-07-26 | 1995-09-20 | Medical Res Council | Improvements in or relating to delivery of nucleic acid |
US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
DE69738454D1 (de) | 1996-05-20 | 2008-02-21 | Us Gov Health & Human Serv | Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden |
US6022863A (en) | 1996-05-21 | 2000-02-08 | Yale University | Regulation of gene expression |
DE69839147T2 (de) | 1997-06-12 | 2009-02-19 | Novartis International Pharmaceutical Ltd. | Künstliche antikörperpolypeptide |
EP1008352A4 (en) | 1997-07-04 | 2005-03-16 | Fujisawa Pharmaceutical Co | Cerebrospinal PROTECTOR |
JP3667047B2 (ja) | 1997-09-12 | 2005-07-06 | キヤノン株式会社 | 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法 |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
US6376471B1 (en) | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
US6060310A (en) | 1997-11-24 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Transcription factor decoy and tumor growth inhibitor |
WO1999031115A1 (en) | 1997-12-16 | 1999-06-24 | The University Of Saskatchewan | Conductive metal-containing nucleic acids |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
DE69910202T2 (de) | 1998-06-02 | 2004-06-17 | Glaxo Group Ltd., Greenford | EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden |
US6818626B1 (en) | 1998-07-17 | 2004-11-16 | Mirus Corporation | Chelating systems for use in the delivery of compounds to cells |
US6423493B1 (en) | 1998-10-26 | 2002-07-23 | Board Of Regents The University Of Texas System | Combinatorial selection of oligonucleotide aptamers |
US6008048A (en) | 1998-12-04 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of EGR-1 expression |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7160869B2 (en) | 1998-12-16 | 2007-01-09 | University Of Saskatchewan | Biologically active metal-containing nucleic acids |
US6140128A (en) | 1998-12-23 | 2000-10-31 | Genentech, Inc. | Preparation of calcium phosphate transfectacons |
US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
US6333408B1 (en) | 1999-03-08 | 2001-12-25 | Kureha Chemical Industry Co., Ltd. | Oligonucleotides inhibitors of PAI-1 MRNA |
FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
US6387620B1 (en) | 1999-07-28 | 2002-05-14 | Gilead Sciences, Inc. | Transcription-free selex |
US6599741B1 (en) | 1999-09-14 | 2003-07-29 | Avontec Gmbh | Modulating transcription of genes in vascular cells |
US6927027B2 (en) | 1999-12-21 | 2005-08-09 | Ingeneus Corporation | Nucleic acid multiplex formation |
US6969704B1 (en) | 2000-08-25 | 2005-11-29 | The Trustees Of Columbia University In The City Of New York | Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject |
AU2002218166A1 (en) | 2000-09-08 | 2002-03-22 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
US6376190B1 (en) | 2000-09-22 | 2002-04-23 | Somalogic, Inc. | Modified SELEX processes without purified protein |
DE10049549A1 (de) * | 2000-10-06 | 2002-05-02 | Markus Hecker | Modulation der Transkription pro-inflammatorischer Genprodukte |
WO2002030355A2 (en) | 2000-10-11 | 2002-04-18 | Laura Kragie | Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
EP1344536A4 (en) | 2000-11-24 | 2005-01-19 | Chugai Pharmaceutical Co Ltd | METHOD FOR REGULATING THE ACTIVITY OF EXPRESSION OF A GENETIC PRODUCT TRANSFERRED INTO A LIVING ORGANISM |
WO2002066071A2 (en) | 2001-01-03 | 2002-08-29 | Thomas Jefferson University | Treatment of tissue fibrosis by blocking the sp1 transcription factor |
WO2002057480A2 (en) | 2001-01-22 | 2002-07-25 | Genta Incorporated | Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers |
TWI308492B (pt) | 2001-02-20 | 2009-04-11 | Anges Mg Inc | |
US20070122401A1 (en) | 2001-03-06 | 2007-05-31 | Andrews William H | Methods and compositions for modulating telomerase reverse transcriptase (tert) expression |
US20030166555A1 (en) | 2001-04-02 | 2003-09-04 | Alberini Cristina M. | Methods and compositions for regulating memory consolidation |
WO2002088171A2 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
EP1298141A1 (en) | 2001-09-27 | 2003-04-02 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Interleukin-4 (IL-4) promoter sequences specifically interacting with IRF-1 and IRF-2 |
DE10148828B4 (de) | 2001-10-04 | 2005-05-19 | Avontec Gmbh | Modulation der Expression STAT-1-abhängiger Gene |
US6663880B1 (en) | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
JP2005519917A (ja) | 2002-02-01 | 2005-07-07 | オメロス コーポレイション | 軟骨分解の全身阻害のための組成物および方法 |
US7244592B2 (en) | 2002-03-07 | 2007-07-17 | Dyax Corp. | Ligand screening and discovery |
CN1240439C (zh) | 2002-03-28 | 2006-02-08 | 南京凯基生物科技发展有限公司 | 肿瘤基因开关药物 |
US20070014840A1 (en) | 2002-04-26 | 2007-01-18 | In-Kyu Lee | Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription |
DE10242319A1 (de) | 2002-09-12 | 2004-03-25 | Avontec Gmbh | Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens |
DE10257421A1 (de) | 2002-12-09 | 2004-07-08 | Grünenthal GmbH | Regulatorische Elemente im 5'-Bereich des VR1-Gens |
MXPA05006169A (es) | 2002-12-09 | 2006-03-30 | American Biosciences | Composiciones y metodos para el suministro de agentes farmacologicos. |
EP1644532A4 (en) | 2003-06-30 | 2007-11-28 | Massachusetts Inst Technology | EGR GENES AS OBJECTIVES FOR DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA |
WO2005027830A2 (en) | 2003-09-12 | 2005-03-31 | Virginia Commonwealth University | Chimeric transcription factor decoy oligonucleotides |
WO2005062854A2 (en) | 2003-12-19 | 2005-07-14 | University Of Cincinnati | Polyamides for nucleic acid delivery |
JP2005336081A (ja) | 2004-05-26 | 2005-12-08 | Anges Mg Inc | Nr2b−nmda受容体の再発現抑制剤 |
US7482158B2 (en) | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
WO2006012625A2 (en) | 2004-07-22 | 2006-02-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Stat3 decoy oligonucleotides and uses therefor |
MX2007003167A (es) | 2004-09-21 | 2007-05-16 | Anesiva Inc | Asministracion de polinucleotidos. |
WO2006035434A2 (en) | 2004-09-28 | 2006-04-06 | Quark Biotech, Inc. | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
EP1803811B1 (en) | 2004-10-22 | 2011-05-11 | AnGes MG, Inc. | Chimeric (double) decoy |
US20060189564A1 (en) | 2004-10-22 | 2006-08-24 | Medtronic, Inc. | Methods and sequences to suppress pro-inflamatory cytokine actions locally to treat pain |
US7585848B2 (en) | 2005-01-11 | 2009-09-08 | Rush University Medical Center | Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc |
WO2006096498A2 (en) | 2005-03-04 | 2006-09-14 | Dana-Farber Cancer Institute, Inc. | Regulation of runx1 for treatment of pain |
EP2086573B1 (en) | 2006-10-09 | 2020-11-25 | Neurofluidics, Inc. | Cerebrospinal fluid purification system |
MX2009011218A (es) | 2007-04-17 | 2010-02-11 | Baxter Int | Microparticulas de acido nucleico para administracion pulmonar. |
JP5646320B2 (ja) | 2007-05-11 | 2014-12-24 | アダイニクス, インコーポレイテッド | 遺伝子発現と疼痛 |
AU2014201462B2 (en) * | 2007-05-11 | 2016-09-29 | Adynxx, Inc. | Gene expression and pain |
GB0906130D0 (en) * | 2008-10-03 | 2009-05-20 | Procrata Biosystems Ltd | Transcription factor decoys |
US8609617B2 (en) * | 2009-09-04 | 2013-12-17 | University Of Miami | KLF family members regulate intrinsic axon regeneration ability |
DK2605794T3 (en) | 2010-08-20 | 2016-10-24 | Replicor Inc | Oligonukleotidchelatkomplekser |
US20140275211A1 (en) * | 2011-06-21 | 2014-09-18 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
DK2734212T3 (da) | 2011-07-20 | 2017-11-06 | Hospira Inc | Sammensætninger omfattende diclofenac til behandling af postoperativ smerte |
CA2872901A1 (en) | 2012-05-10 | 2013-11-14 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
SI2849798T1 (sl) | 2012-05-18 | 2021-08-31 | Replicor Inc. | Oligonukleotidni kelatni kompleksni polipeptidni sestavki in postopki |
JP6705807B2 (ja) | 2014-08-15 | 2020-06-03 | エーダイニクス インコーポレイテッド | 疼痛を治療するためのオリゴヌクレオチドデコイ |
US20200017853A1 (en) | 2016-02-29 | 2020-01-16 | Adynxx, Inc. | Compositions and methods for pain amelioration via modification of gene expression |
CA3091832A1 (en) | 2018-02-23 | 2019-08-29 | Adynxx Sub, Inc. | Compositions and methods for pain amelioration in patient population that scores high on the pain catastrophizing scale |
-
2015
- 2015-08-14 JP JP2017508487A patent/JP6705807B2/ja not_active Expired - Fee Related
- 2015-08-14 US US15/504,191 patent/US10287583B2/en not_active Expired - Fee Related
- 2015-08-14 WO PCT/US2015/045268 patent/WO2016025829A1/en active Application Filing
- 2015-08-14 EP EP15832083.8A patent/EP3180434B1/en not_active Not-in-force
- 2015-08-14 BR BR112017002629-5A patent/BR112017002629A2/pt not_active Application Discontinuation
- 2015-08-14 ES ES15832083T patent/ES2750689T3/es active Active
- 2015-08-14 RU RU2017108238A patent/RU2017108238A/ru not_active Application Discontinuation
- 2015-08-14 EP EP19186119.4A patent/EP3626822A1/en not_active Withdrawn
- 2015-08-14 CA CA2957250A patent/CA2957250A1/en not_active Abandoned
- 2015-08-14 AU AU2015301491A patent/AU2015301491A1/en not_active Abandoned
- 2015-08-14 PT PT158320838T patent/PT3180434T/pt unknown
- 2015-08-14 CN CN201580042835.6A patent/CN106661578B/zh not_active Expired - Fee Related
-
2019
- 2019-03-19 US US16/358,013 patent/US10683502B2/en active Active
-
2020
- 2020-05-14 JP JP2020084841A patent/JP2020141688A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2017108238A (ru) | 2018-09-17 |
CN106661578A (zh) | 2017-05-10 |
AU2015301491A1 (en) | 2017-02-02 |
EP3180434A4 (en) | 2018-04-04 |
US20190276825A1 (en) | 2019-09-12 |
EP3180434B1 (en) | 2019-07-17 |
EP3626822A1 (en) | 2020-03-25 |
PT3180434T (pt) | 2019-10-29 |
CA2957250A1 (en) | 2016-02-18 |
US10287583B2 (en) | 2019-05-14 |
CN106661578B (zh) | 2020-08-04 |
RU2017108238A3 (pt) | 2019-09-18 |
JP2020141688A (ja) | 2020-09-10 |
US20170247694A1 (en) | 2017-08-31 |
EP3180434A1 (en) | 2017-06-21 |
WO2016025829A1 (en) | 2016-02-18 |
ES2750689T3 (es) | 2020-03-26 |
US10683502B2 (en) | 2020-06-16 |
JP6705807B2 (ja) | 2020-06-03 |
JP2017529834A (ja) | 2017-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017002629A2 (pt) | decoys de oligonucleotídeo para o tratamento de dor | |
CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
BR112017011923A2 (pt) | bactéria modificada para tratar doenças associadas com hiperamonemia | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
BR112017017727A8 (pt) | Heterociclos bicíclicos como inibidores de fgfr4 | |
BR112017002332A2 (pt) | terapia de combinação para o tratamento de um paramixovírus | |
NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
BR112017006664A2 (pt) | terapias de combinação | |
BR112017015864A2 (pt) | compostos e métodos para modular a expressão de tmprss6 | |
BR112016003201A2 (pt) | inibidores de grp94 seletivos e usos dos mesmos | |
BR112017000301A2 (pt) | tratamento de leucemia com inibidores de histona desacetilase | |
BR112016022855A2 (pt) | composições e métodos para modular a expressão de pkk | |
GB2541571A (en) | Pharmaceutical compositions | |
BR112015019995A2 (pt) | Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer | |
PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
EA201790802A1 (ru) | Соединения против tnf | |
BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
MX2017011277A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
BR112017000730B8 (pt) | Derivados de pirrolidinona como inibidores de metap-2, e medicamentos | |
EA201790773A1 (ru) | Композиции и способы для ингибирования биологической активности растворимых биомолекул | |
CL2018001085A1 (es) | Derivados de indolin-2-ona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |